Concepedia

Publication | Open Access

Rifampin Pharmacokinetics and Safety in Preterm and Term Infants

DOIFull Paper Access

12

Citations

35

References

2019

Year

P. Brian Smith, C. Michael Cotten, Mark L. Hudak, Janice E. Sullivan, Brenda B. Poindexter, Michael Cohen‐Wolkowiez, Felix Boakye‐Agyeman, Andrew Lewandowski, Ravinder Anand, Daniel K. Benjamin,
Antimicrobial Agents and Chemotherapy

Abstract

Rifampin is active against methicillin-resistant staphylococcal species and tuberculosis (TB). We performed a multicenter, prospective pharmacokinetic (PK) and safety study of intravenous rifampin in infants of <121 days postnatal age (PNA).

References

YearCitations

Page 1